Ernexa Therapeutics Inc. (ERNA): Nasdaq/NYSE listing notice — Eterna Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure period until June 30, 2025

Ernexa Therapeutics Inc.

Notice received December 30, 2024: closing bid price below $1 for 30 consecutive business days.
Company has until June 30, 2025 to regain compliance for 10 consecutive business days.
If not cured, may request a second 180-day period if other listing standards are met.
Stock continues to trade on Nasdaq under symbol ERNA with no immediate delisting.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi

View on SEC.gov

Browse all listing & compliance notices →

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-000246

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.